# PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026
Canonical URL: https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-report-second-quarter-2026-financial-results-on-august-4t-255b7bdd
Ticker: PRCT
Company: PROCEPT BioRobotics
Source: PROCEPT BioRobotics
Published: 2026-07-14 20:05 EST
## Summary

PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused...

## Article Body
PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2026 after market close on Tuesday, August 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

Webcast link for interested listeners: https://edge.media-server.com/mmc/p/8fznodv2

Dial-in registration for sell-side research analysts: https://register-conf.media-server.com/register/BI52750114763b4e46862d9605fe2f2b01

Live audio of the webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com .

An archived recording will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com . Each webcast will be available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The Company manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. In addition to its leadership in BPH treatment, the Company is pursuing clinical research initiatives in prostate cancer utilizing investigational applications of its robotic and AI-enabled technologies. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:

Marissa Bych Managing Director Gilmartin Group LLC Marissa@gilmartinir.com
## Recent Company News
- 2026-07-14 20:05 EST — [PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026](https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-report-second-quarter-2026-financial-results-on-august-4t-255b7bdd) — Source: PROCEPT BioRobotics
- 2026-05-28 12:00 EST — [PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval](https://biopharmsignal.com/news/PRCT/procept-biorobotics-advances-prostate-cancer-program-with-water-iv-study-enrollm-de942ff2) — Source: PROCEPT BioRobotics
- 2026-05-14 12:00 EST — [AUA Guidelines Strengthen Recommendation for Aquablation® Therapy](https://biopharmsignal.com/news/PRCT/aua-guidelines-strengthen-recommendation-for-aquablation-therapy-b17aee34) — Source: PROCEPT BioRobotics
- 2026-04-30 20:03 EST — [PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June](https://biopharmsignal.com/news/PRCT/procept-biorobotics-to-attend-three-upcoming-investor-conferences-in-may-june-336852ab) — Source: PROCEPT BioRobotics
- 2026-04-29 20:03 EST — [PROCEPT BioRobotics Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PRCT/procept-biorobotics-reports-first-quarter-2026-financial-results-c24cd67e) — Source: PROCEPT BioRobotics
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)